BNP Paribas Exane Cuts Zoetis (NYSE:ZTS) Price Target to $110.00

Zoetis (NYSE:ZTS) had its price objective decreased by BNP Paribas Exane from $146.00 to $110.00 in a research note released on Tuesday morning,Benzinga reports. BNP Paribas Exane currently has an outperform rating on the stock.

Several other equities research analysts also recently commented on ZTS. William Blair restated a “market perform” rating on shares of Zoetis in a report on Thursday, August 6th. Citigroup reduced their price target on shares of Zoetis from $145.00 to $112.00 and set a “buy” rating for the company in a research report on Monday, May 18th. Barclays decreased their price target on shares of Zoetis from $136.00 to $85.00 and set an “equal weight” rating for the company in a research note on Wednesday, July 1st. Argus restated a “hold” rating on shares of Zoetis in a report on Wednesday, May 27th. Finally, HSBC dropped their price objective on shares of Zoetis from $140.00 to $95.00 and set a “buy” rating on the stock in a research note on Monday, July 6th. Eight equities research analysts have rated the stock with a Buy rating, nine have assigned a Hold rating and two have issued a Sell rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Hold” and a consensus target price of $109.62.

Zoetis Price Performance

ZTS stock opened at $75.62 on Tuesday. The stock has a market capitalization of $31.25 billion, a PE ratio of 12.46, a price-to-earnings-growth ratio of 1.27 and a beta of 0.74. The company’s 50-day moving average is $76.41 and its 200-day moving average is $99.19. The company has a debt-to-equity ratio of 2.87, a current ratio of 3.08 and a quick ratio of 1.84. Zoetis has a 1 year low of $71.45 and a 1 year high of $160.48.

Zoetis (NYSE:ZTS) last issued its earnings results on Thursday, August 6th. The company reported $1.87 EPS for the quarter, beating analysts’ consensus estimates of $1.85 by $0.02. Zoetis had a return on equity of 74.89% and a net margin of 27.49%.The business had revenue of $2.47 billion during the quarter, compared to analyst estimates of $2.50 billion. During the same period in the previous year, the company posted $1.76 EPS. The firm’s revenue was down .2% compared to the same quarter last year. Zoetis has set its FY 2026 guidance at 6.150-6.250 EPS. Equities research analysts expect that Zoetis will post 6.19 EPS for the current fiscal year.

Zoetis Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Tuesday, September 1st. Investors of record on Monday, July 20th will be given a dividend of $0.53 per share. The ex-dividend date of this dividend is Monday, July 20th. This represents a $2.12 annualized dividend and a dividend yield of 2.8%. Zoetis’s payout ratio is presently 34.93%.

Institutional Investors Weigh In On Zoetis

Institutional investors and hedge funds have recently bought and sold shares of the stock. Cullen Capital Management LLC purchased a new position in Zoetis during the 2nd quarter worth $801,000. Dearborn Partners LLC purchased a new stake in shares of Zoetis in the second quarter valued at about $12,639,000. Ally Financial Inc. bought a new position in shares of Zoetis during the second quarter valued at about $790,000. Westport Asset Management Inc. bought a new position in shares of Zoetis during the second quarter valued at about $287,000. Finally, Flossbach Von Storch SE purchased a new position in Zoetis during the second quarter worth about $302,601,000. 92.80% of the stock is owned by hedge funds and other institutional investors.

Zoetis News Summary

Here are the key news stories impacting Zoetis this week:

• Positive Sentiment: The U.S. Food and Drug Administration granted Emergency Use Authorization for Zoetis’ Simparica Trio to treat New World screwworm infestations in dogs and puppies. The approval expands the product’s potential use and provides Zoetis with an immediate role in addressing a serious animal-health threat. Zoetis Receives Emergency Use Authorization for Simparica Trio
• Positive Sentiment: The FDA decision was reported as the main reason for the stock’s advance, while the product’s established flea-and-tick distribution and veterinary network could help support adoption. Zoetis gets US FDA emergency use nod for treatment for screwworm in dogs
• Neutral Sentiment: Zoetis recently reported quarterly adjusted EPS of $1.87, slightly above consensus, but revenue of $2.47 billion fell short of expectations and declined modestly year over year. Management’s full-year 2026 EPS outlook remains $6.15–$6.25, limiting the immediate earnings upside narrative.
• Negative Sentiment: Investor attention remains focused on softer U.S. companion-animal demand, fewer veterinary visits, price-sensitive pet owners and competitive pressure in dermatology and parasiticide products. These concerns have contributed to lower expectations for the company’s recovery. Zoetis slides as investors remain focused on softer pet-care demand and competitive pressure
• Negative Sentiment: BNP Paribas Exane lowered its expectations for Zoetis, while Zacks Research downgraded the stock to “strong sell.” The broader analyst consensus is reported as “hold,” signaling limited confidence in near-term upside. BNP Paribas Exane Has Lowered Expectations for Zoetis Stock Price

About Zoetis

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.